Global Prostate Cancer Drugs Market 2016-2020


#892967

91pages

Technavio

$ 2500

In Stock

About Prostate Cancer Drugs
Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other parts of the body. The cells that spread might bind to other tissues, form new tumors, and sometimes damage those tissues as well. When prostate cancer cells spread from their original place to another, the new tumor formed also has the same kind of abnormal cells.

Technavios analysts forecast the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global prostate cancer drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Prostate Cancer Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Astellas Pharma
AstraZeneca
Johnson & Johnson
Sanofi

Other prominent vendors
Active Biotech
ADC Therapeutics
Advantagene
Advaxis Pharmaceuticals
ANI Pharmaceuticals
ArQule
Athenex Pharmaceuticals
Bavarian Nordic
Bayer HealthCare
BHR Pharma
BMS
Boehringer Ingelheim
Camurus
Cleveland BioLabs
CureVac
Dendreon
Dextech Medical
Eisai
Endo Pharmaceuticals
Ferring Pharmaceutical
Foresee Pharmaceuticals
GlaxoSmithKline
GTx
Innocrin Pharmaceutical
Inspyr Therapeutics
Io Therapeutics
Lidds AB
Merck Group
Myovant Sciences
Northwest Biotherapeutics
Novartis
Nymox Pharmaceuticals
OncoGenex
Oncolytics Biotech
Orion
Pharmamar
Progenics Pharmaceuticals
Sotio
Spectrum Pharmaceuticals
Synta
Takeda Pharmaceuticals
Teva Pharmaceutical
Tokai Pharmaceuticals

Market driver
Physicians preference toward adopting hormonal therapies
For a full, detailed list, view our report

Market challenge
Presence of alternative treatment approaches
For a full, detailed list, view our report

Market trend
Emergence of targeted therapies and immunotherapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.







Table of Contents
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding disease
Types of prostate cancer
Diagnosis
Key buying criteria
PART 06: Pipeline analysis
PART 07: Market landscape
Global prostate cancer therapeutics market
Five forces analysis
PART 08: Market segmentation by therapy
Hormonal therapy
Chemotherapy
Immunotherapy
Targeted therapy
PART 09: Geographical segmentation
Global prostate cancer drugs market by geographical segmentation 2015-2020
Prostate cancer drugs market in Americas
Prostate cancer drugs market in EMEA
Prostate cancer drugs market in APAC
PART 10: Market drivers
Physicians preference toward adopting hormonal therapies
Development of drugs with novel mechanism of action
Availability of large patient pool
PART 11: Impact of drivers
PART 12: Market challenges
Presence of alternative treatment approaches
High cost of drugs
Adverse side-effects of drugs
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
Competitive scenario
PART 16: Key vendor analysis
Johnson & Johnson
Astellas Pharma
AstraZeneca
Sanofi
AbbVie
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global prostate cancer drugs market
Exhibit 03: Snapshot of prostate cancer
Exhibit 04: Types of prostate cancer
Exhibit 05: Main diagnostic procedures to determine presence of prostate cancer
Exhibit 06: Key buying criteria for prostate cancer drugs
Exhibit 07: Factors affecting the adoption rates of prostate cancer drugs 2015 and 2020
Exhibit 08: Pipeline analysis of key vendors in global prostate cancer drugs market
Exhibit 09: Percentage share of drug candidates by stage of development
Exhibit 10: Phase III pipeline portfolio: Global prostate cancer drugs market
Exhibit 11: Phase II pipeline portfolio: Global prostate cancer drugs market
Exhibit 12: Phase I pipeline portfolio: Global prostate cancer drugs market
Exhibit 13: Global prostate cancer therapeutics market snapshot
Exhibit 14: Analysis of global prostate cancer therapeutics market
Exhibit 15: Pipeline of global prostate cancer drugs
Exhibit 16: Global prostate cancer drugs market 2015-2020 ($ billions)
Exhibit 17: Opportunity analysis of global prostate cancer drugs market
Exhibit 18: Opportunity analysis in developed and emerging markets
Exhibit 19: Five forces analysis
Exhibit 20: Segmentation of global prostate cancer drugs market by therapy 2015
Exhibit 21: Life cycle analysis of key segments in global prostate cancer drugs market
Exhibit 22: Analysis of prostate cancer drugs market by geography
Exhibit 23: Segmentation of prostate cancer drugs market based on geography 2015 and 2020
Exhibit 24: Prostate cancer drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 25: Prostate cancer drugs market size and forecast in Americas 2015-2020 ($ billions)
Exhibit 26: Key trends across various countries in Americas
Exhibit 27: Incidence of prostate cancer in key countries of EMEA 2012
Exhibit 28: Prostate cancer drugs market size and forecast in EMEA 2015-2020 ($ billions)
Exhibit 29: Trends in prostate cancer therapeutics market in EMEA
Exhibit 30: Prostate cancer drugs market in APAC 2015-2020 ($ billions)
Exhibit 31: Key drivers and challenges in APAC
Exhibit 32: Performance of hormone therapies in 2015
Exhibit 33: Key drugs with novel mechanism of action
Exhibit 34: Potential older population with prostate cancer (65 years and above)
Exhibit 35: Impact of drivers
Exhibit 36: Alternative therapies
Exhibit 37: Costs of key prostate cancer drugs ($ thousands)
Exhibit 38: Some of the side-effects of drugs
Exhibit 39: Force field analysis of drivers and challenges in global prostate cancer drugs market
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Trend analysis in global prostate cancer drugs market
Exhibit 42: Key highlights of targeted therapies and immunotherapies
Exhibit 43: New advancements in diagnosis of prostate cancer
Exhibit 44: Key late stage pipeline candidates
Exhibit 45: Competitive structure analysis of global prostate cancer drugs market 2015
Exhibit 46: Market share analysis 2015
Exhibit 47: Performance/initiatives of existing and upcoming vendors in global prostate cancer drugs market
Exhibit 48: Competitive analysis in global prostate cancer therapeutics market
Exhibit 49: Market penetration of various prostate cancer drug manufacturers worldwide 2015
Exhibit 50: Regional analysis of vendors in global prostate cancer drugs market
Exhibit 51: Johnson & Johnson: Key highlights
Exhibit 52: Johnson & Johnson: Strength assessment
Exhibit 53: Johnson & Johnson: Strategy assessment
Exhibit 54: Johnson & Johnson: Opportunity assessment
Exhibit 55: Johnson & Johnson: YoY revenue comparison of Zytiga (Global) 2013-2015 ($ billions)
Exhibit 56: Astellas Pharma: Key highlights
Exhibit 57: Astellas Pharma: Strength assessment
Exhibit 58: Astellas Pharma: Strategy assessment
Exhibit 59: Astellas Pharma: Opportunity assessment
Exhibit 60: Astellas Pharma: YoY revenue comparison of Xtandi 2014-2015 ($ billions)
Exhibit 61: AstraZeneca: Key highlights
Exhibit 62: AstraZeneca: Strength assessment
Exhibit 63: AstraZeneca: Strategy assessment
Exhibit 64: AstraZeneca: Opportunity assessment
Exhibit 65: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
Exhibit 66: AstraZeneca: Geographic segmentation of Zoladex 2015
Exhibit 67: AstraZeneca: YoY revenue and growth rate of Casodex 2013-2015 ($ millions)
Exhibit 68: AstraZeneca: Geographic segmentation of Zoladex 2015
Exhibit 69: Sanofi: Key highlights
Exhibit 70: Sanofi: Strength assessment
Exhibit 71: Sanofi: Strategy assessment
Exhibit 72: Sanofi: Opportunity assessment
Exhibit 73: Sanofi: YoY revenue and growth rate of Jevtana 2013-2015 ($ millions)
Exhibit 74: Sanofi: YoY revenue and growth rate of Taxotere 2013-2015 ($ millions)
Exhibit 75: AbbVie: Key highlights
Exhibit 76: AbbVie: Strength assessment
Exhibit 77: AbbVie: Strategy assessment
Exhibit 78: AbbVie: Opportunity assessment
Exhibit 79: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)